Table 1. Summary of splicing events in prostate cancer.
Cell lines and patient samples with known African American ancestry are in bold and underlined. Abbreviations: ARV7, androgen receptor splice variant 7; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; SRSF1, serine/arginine splicing factor 1; ARv567es, androgen receptor variant (exons) 5,6,7 exon skipping; MED1, mediator complex subunit 1; FGFR2, fibroblast growth factor receptor 2; VEGF, vascular endothelial growth factor; BCL2L1, B-cell lymphoma 2-like 1; Sam68, Src-associated substrate in mitosis of 68 kDa; SH3GLB1, SH3 domain-containing GRB2-like protein B1; SRRM4, serine/arginine repetitive matrix 4; CCND1, cyclin D1; SRSF1, serine/arginine splicing factor 1; ST6GalNAc1, ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 1; PCSK6, proprotein convertase sutilisin/kexin type 6; CLK1, CDC like kinase 1; 17βHSD4, 17β-Hydroxysteroid dehydrogenase type 4; PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta; AA, African American; EA, European American.
| Reference | Spliced gene (Splicing factor) |
Alternative splicing event |
Cell lines and/or patient samples | |
|---|---|---|---|---|
| Cao et al. 2014 | ARV7 | Cryptic exon | LNCaP, 22Rv1, PC-3 | |
| Antonarakis et al. 2014 | ARV7 (hnRNPA1) | Cryptic exon | Patients (ethnicity N/A) | |
| Ko et al. 2014 | ARV7 (hnRNPA1) | Cryptic exon | PC-3 | |
| Nadiminty et al. 2015 | ARV7 (hnRNPA1) | Cryptic exon | LNCaP, 22Rv1, VCaP, C4-2B | |
| Tummala et al. 2017 | ARV7 (hnRNPA1) | Cryptic exon | 22Rv1, C4-2B | |
| Stockley et al. 2015 | ARV7 (Sam68, SRSF1) | Cryptic exon | 22Rv1, VCaP, CWR22, PC3-M | |
| Sun et al. 2010 | ARv567es | Exon skipping | M12, LNCaP, LuCaP | |
| Hörnberg et al. 2011 | ARv567es | Exon skipping | Patients (ethnicity N/A) | |
| Liu et al. 2015 | ARv567es (MED1) | Exon skipping | LNCaP, M12 | |
| Sahadevan et al. 2007 | FGFR2 | Mutually exclusive exons | PC-3, DU145, patients (ethnicity N/A) | |
| Carstens et al. 1997 | FGFR2 | Mutually exclusive exons | LNCaP, PC-3, DU145, DUP9479, DUKAP-1, DUPKAP-2 | |
| Gnanapragasam et al. 2003 | FGFR2 | Mutually exclusive exons | Patients (ethnicity N/A) | |
| Woolard et al. 2004 | VEGF | Alternative 3’ splice site | Patients (ethnicity N/A) | |
| Rennel et al. 2008 | VEGF | Alternative 3’ splice site | PC-3, patients (ethnicity N/A) | |
| Mavrou et al. 2015 | VEGF | Alternative 3’ splice site | PC3, LNCaP, DU145 | |
| Mercatante, Mohler, & Kole 2002 | BCL2L1 | Alternative 5’ splice site | PC-3 | |
| Busà et al. 2007 | BCL2L1 (SAM68) | Alternative 5’ splice site | LNCaP, patients (ethnicity N/A) | |
| Gan et al. 2018 | SH3GLB1 (SRRM4) | Alternative 5’ splice site, exon skipping | LNCaP, 22RV1, PC-3, DU145, NCI-H660, LNCaP95, patients (ethnicity N/A) | |
| Augello et al. 2013 | CCND1 | Intron retention | LNCaP, VCaP, LAPC4, PC-3, C4-2 | |
| Olshavsky et al. 2010 | CCND1 (SRSF1) | Intron retention | LNCaP, LAPC4 | |
| Paronetto et al. 2010 | CCND1 | Intron retention | PC3, LNCaP | |
| Munkley et al. 2015 | ST6GalNAc1 | Exon skipping | LNCaP, VCaP, PC-3, 22Rv1, DU145, LNCaP-AI, and LNCaP-cdxR, BPH-1 | |
| Couture et al. 2017 | PCSK6 | Exon skipping | DU145, LNCaP, patients (ethnicity N/A) | |
| Uzor et al. 2018 | CLK1 | Exon skipping, intron retention | PC-3, DU145, VCaP | |
| Ko et al. 2018 | 17βHSD4 | Alternative 5’ splice site, exon skipping | LNCaP, LAPC4, VCaP, PC-3, DU145, RWPE-1, 22Rv1, patients (ethnicity N/A) | |
| Wang et al. 2017 | PIK3CD | Exon skipping | MDA PCa 2b, VCaP, LNCaP, PC-3, Patients (AA, EA) |